Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF as a therapeutic target: a patent review (2006 - 2012).

Expert opinion on therapeutic patents - 1 Feb 2013

Zambon Alfonso, Niculescu-Duvaz Dan, Niculescu-Duvaz Ion, Marais Richard, Springer Caroline J

Abstract excerpt

INTRODUCTION: After its identification as an oncogene in 2002, mutant BRAF has become the target of a number of drug discovery programmes, primarily aimed at the treatment of late stage or unresectable melanoma. Some of the drugs thus developed, such as vemurafenib and dabrafenib, show impressive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Design
Share to Molecular Structure
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Patents as Topic

Share to Patient Selection

Share to Precision Medicine

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 23294221
DOI: 10.1517/13543776.2013.741593

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23294221-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF as a therapeutic target: a patent review (2006 - 2012).PMID 23294221Read ↗

Vemurafenib: the first drug approved for BRAF-mutant cancer.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

[Progress of anti-tumor study based on BRAF].Semantic proximity Read ↗

Which drug, and when, for patients with BRAF-mutant melanoma?Semantic proximity Read ↗

Beyond BRAF: where next for melanoma therapy?Semantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

BRAF as a potential therapeutic target in melanoma and other malignancies.Semantic proximity Read ↗

BRAF as a target for cancer therapy.Semantic proximity Read ↗

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.Semantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

BRAF Inhibitors and MelanomaSemantic proximity Read ↗

BRAF in melanoma: current strategies and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.